Posters

Psych Congress 2019
Efficacy and Safety of a Delayed-Release and Extended-Release Methylphenidate Formulation in Children With ADHD: Results From a Pivotal Phase 3 Trial in a Naturalistic Setting
Psych Congress 2019
Efficacy and Safety of an Asenapine Transdermal System (HP-3070) for Treatment of Adults with Schizophrenia: A Phase 3 Randomized, Placebo-Controlled, Inpatient Study
Psych Congress 2019
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Adult Patients at Imminent Risk for Suicide: ASPIRE-1, a Phase 3 Randomized Study
Psych Congress 2019
Use of Patient Health Questionnaire to Predict Relapses Among Patients With Treatment-Resistant Depression Treated With Esketamine + Oral Antidepressant
Psych Congress 2019
CLARITY: A Phase 2 Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder
Psych Congress 2019
Extended-Release Viloxazine (SPN-812) 200 mg or 400 mg for the Treatment of ADHD in Adolescents: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P302)
Psych Congress 2019
Pooled Analysis From 12-Week Randomized, Controlled Studies of Solriamfetol in the Treatment of Excessive Daytime Sleepiness in Participants With Obstructive Sleep Apnea or Narcolepsy
Psych Congress 2019
Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents With Schizophrenia: Post-hoc Analysis of a Two Year, Open-label Study
Psych Congress 2019
Demographic Characteristics, Healthcare Cost, and Treatment Patterns Among Patients With Major Depressive Disorder and Suicidal Ideation or Suicide Attempt Who Received Treatment at a Hospital
Psych Congress 2019
Treatment Experiences of Individuals With Bipolar I Disorder: Findings From an Online Survey
Psych Congress 2019
Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study
Psych Congress 2019
Evolution of a Study of Bilateral Prefrontal Transcranial Magnetic Stimulation (TMS) to Treat the Symptoms of Mild TBI (mTBI) and PTSD: Research Methods, Participant Demographics, and Tolerability
Psych Congress 2019
Assessment of Health-Related Quality of Life and Health Status in Patients With Treatment Resistant Depression Treated With Esketamine Nasal Spray Plus Oral Antidepressant Using European Quality of Life Group-5-Dimension-5-Level
Psych Congress 2019
Prevalence, Incidence and Economic Burden of Schizophrenia Among Medicaid Beneficiaries
Psych Congress 2019
Extended-Release Viloxazine (SPN-812) 200 mg or 400 mg for the Treatment of ADHD in Children: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P303)
Psych Congress 2019
Barriers and Drivers of Adopting a Digital Medication Adherence Technology: Understanding the Factor Analysis Results
Psych Congress 2019
Incremental Burden of Relapse in Patients with Major Depressive Disorder
Psych Congress 2019
Treatment Experiences of Individuals With Schizophrenia: Findings From an Online Survey
Psych Congress 2019
Impact of Treatment With Esketamine Nasal Spray in Patients With Treatment Resistant Depression and Comorbid Anxiety: A Post-hoc Pooled Analysis of the TRANSFORM 1 and 2 Trials
Psych Congress 2019
Repetitive Transcranial Magnetic Stimulation as a Protective Measure Against Early-Onset Alzheimer’s Disease: A Case Report
Psych Congress 2019
Determining Meaningful Change in Depression Symptoms Assessed With the Patient Health Questionnaire (PHQ-9) and Sheehan Disability Scale (SDS) Among Patients With Treatment Resistant Depression in Trials of Esketamine Nasal Spray
Psych Congress 2019
Recent Patterns of Relapse and Associated Costs in Schizophrenia Patients Initiating Atypical Antipsychotics
Psych Congress 2019
Hospitalization Risk in Pediatric Bipolar Patients Treated with Lurasidone vs. Other Oral Atypical Antipsychotics: A Real-World Retrospective Claims Database Study
Psych Congress 2019
A Comparison of Barriers and Drivers Between Prescribing and Non-Prescribing Psychiatric Care Providers Regarding Use of Digital Medication Adherence Platforms
Psych Congress 2019
Response Rates of Esketamine Nasal Spray Plus an Oral Antidepressant Among Patients Not Meeting Study Criteria for Early Response to Treatment
Back to Top